CD3

North Chicago, Illinois, USA, October 27, 2026 AbbVie has submitted a Biologics License Application (BLA) to the U.S. Food...

WATERTOWN, Mass. — September 25, 2026 C4 Therapeutics presented new biomarker data from clinical trials of cemsidomide in patients...

SAN DIEGO and SUZHOU, China — September 22, 2026 Adagene announced that China’s National Medical Products Administration (NMPA) has...

CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...

PHILADELPHIA — September 9, 2026 Context Therapeutics Inc. announced that the first patient has been dosed in the Phase...

North Chicago, Illinois, USA, September 3, 2026 AbbVie has announced positive topline results from the Phase 3 CERVINO trial,...

Tokyo, Japan, August 25, 2026 Astellas Pharma Inc. announced that the first patient has been dosed in a Phase...

Shanghai and Hong Kong, China, August 25, 2026 Antengene Corporation Limited announced that the Phase I ATTRACT clinical study...

Beerse, Belgium, August 21, 2026 Johnson & Johnson announced that the European Commission (EC) has approved an indication extension...

Cambridge, Massachusetts; Rotterdam, Netherlands; and Shanghai, China, August 18, 2026 Harbour BioMed (HKEX: 02142) announced that China’s National Medical...